Hims & Hers Files 8-K

TL;DR

HIMS filed an 8-K on 9/9 for an event on 9/5. Details pending.

AI Summary

Hims & Hers Health, Inc. filed an 8-K on September 9, 2024, reporting an event that occurred on September 5, 2024. The filing pertains to "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates a regulatory update from Hims & Hers Health, Inc. to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational details that would indicate high risk.

Key Players & Entities

• Hims & Hers Health, Inc. (company) — Registrant
• September 5, 2024 (date) — Earliest event reported
• September 9, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 2269 Chestnut Street , #523 San Francisco , CA 94123 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — hich registered Class A Common Stock, $0.0001 par value HIMS New York Stock Excha

Filing Documents

• tm2422489d3_8k.htm (8-K) — 25KB
• tm2422489d3_ex5-1.htm (EX-5.1) — 9KB
• tm2422489d3_ex5-1img001.jpg (GRAPHIC) — 4KB
• tm2422489d3_ex5-1img002.jpg (GRAPHIC) — 6KB
• 0001104659-24-098228.txt ( ) — 221KB
• hims-20240905.xsd (EX-101.SCH) — 3KB
• hims-20240905_lab.xml (EX-101.LAB) — 33KB
• hims-20240905_pre.xml (EX-101.PRE) — 22KB
• tm2422489d3_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On September 9, 2024, Hims & Hers Health, Inc. (the "Company") filed a prospectus supplement dated September 9, 2024 (the "Prospectus Supplement"), which forms part of the Company's automatic "shelf" Registration Statement on Form S-3 (File No. 333-282008), which was filed on September 9, 2024 with the Securities and Exchange Commission. The Prospectus Supplement supplements the base prospectus contained in the Registration Statement, and was filed to register 976,341 shares of the Company's Class A common stock (the "Resale Shares") issued to Nivagen Pharmaceuticals, Inc. ("Nivagen") in connection with the acquisition by the Company (the "Medisource Acquisition") of 100% of the membership interests of Seaview Enterprises LLC (d/b/a MedisourceRx) ("Medisource") pursuant to the purchase agreement dated July 5, 2024, by and among the Company, Nivagen, and Medisource (the "Purchase Agreement"). The Medisource Acquisition closed on September 5, 2024. The offering of the Resale Shares was made pursuant to an exemption from registration under the Securities Act of 1933, as amended (the "Securities Act"). The Prospectus Supplement was filed in accordance with the Purchase Agreement. A copy of the opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP relating to the legality of the Resale Shares is filed herewith as Exhibit 5.1.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 5.1 Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP 23.1 Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HIMS & HERS HEALTH, INC. Date: September 9, 2024 By: /s/ Andrew Dudum Andrew Dudum Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR